ReviewInflammopharmacology2026
Gold nanoparticles (AuNPs) as emerging anti-inflammatory agents: mechanisms, therapeutic advances, and future directions-a systematic review and meta-analysis.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation contributes significantly to the development of several chronic disorders, including rheumatoid arthritis, psoriasis, cardiovascular diseases, and neurodegenerative disorders. Although conventional anti-inflammatory medications remain effective, prolonged use is often linked various side effects. In recent years, gold nanoparticles (AuNPs) have emerged as a promising nanotherapeutic agent because of their unique physicochemical and biological properties. Green-synthesized AuNPs further showed improved biocompatibility and enhanced therapeutic efficacy due to the presence of bioactive phytochemicals. This review highlights recent advances (2015-2026) in the anti-inflammatory activity through both a literature review and meta-analysis. Findings from in-vitro and in-vivo studies showed that AuNPs can downregulate pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, nitric oxide (NO), and prostaglandin E2 (PGE2) by modulating signaling pathways including NF-κB, MAPK, and JAK/STAT signaling pathways. AuNPs also reduce oxidative stress and promote anti-inflammatory macrophage polarization. Meta-analysis included total 20 in-vivo studies, among which 18 studies evaluated for pro-inflammatory cytokines, while 9 studies were assessed for anti-inflammatory cytokines, collectively supporting the therapeutic potential of AuNPs in the treatment of inflammatory disorders.
Indexed as
Identifiers
42489790What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.